Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 5

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
929,525) 
     (4,929,525)
  
    Issuance of stock upon vesting of restricted shares 
     1,100  
     11  

     11 
  
    Realized and unrealized gains (losses), net, on investments securities 
     -  
     -  
     -  
     -  
     -  
     72,305  
     -  
     72,305 
  
    Stock-based compensation expense 
     -  
     -  
     (30,690) 
     -  
     -  
     -  
     -  
     (30,690)
  
    Balance at March
31, 2024 (unaudited) 
     9,400,911  
    $94,009  
    $401,470,148  
     22  
    $(85,188) 
    $133,101  
    $(393,112,327) 
    $8,499,743 
  
    Balance 
     9,400,911  
    $94,009  
    $401,470,148  
     22  
    $(85,188) 
    $133,101  
    $(393,112,327) 
    $8,499,743 

See accompanying notes to the unaudited condensed
consolidated financial statements.

7

IMUNON, INC.

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(UNAUDITED)

MARCH 31, 2025 

Note 1. Business Description

Imunon, Inc. (“Imunon” or the “Company”)
is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural
mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating
approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®,
is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising.
The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit